百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ONC 百济神州

盘后交易 07-18 16:21:50 EDT

294.55

+4.20

+1.45%

盘后294.55

+0.000.00%

16:10 EDT

最高300.00	最低293.51	成交量89.35万
今开297.50	昨收290.35	日振幅2.24%
总市值348.90亿	流通市值222.51亿	总股本1.18亿
成交额2.65亿	换手率1.18%	流通股本7,554万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":294.55,"timestamp":1752868800000,"preClose":290.35,"halted":0,"volume":893451,"hourTrading":{"tag":"盘后","latestPrice":294.55,"preClose":294.55,"latestTime":"16:10 EDT","volume":3557,"amount":1047711.1487,"timestamp":1752869403876},"delay":0,"floatShares":75541600,"shares":118450658,"eps":-3.70325,"marketStatus":"盘后交易","change":4.2,"latestTime":"07-18 16:21:50 EDT","open":297.5,"high":300,"low":293.51,"amount":264744005.2062,"amplitude":0.022352,"askPrice":298.25,"askSize":8,"bidPrice":293,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1752883200000},"marketStatusCode":4,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":290.35,"preHourTrading":{"tag":"盘前","latestPrice":299.25,"preClose":290.35,"latestTime":"09:29 EDT","volume":3281,"amount":982962.59878,"timestamp":1752845389593},"postHourTrading":{"tag":"盘后","latestPrice":294.55,"preClose":294.55,"latestTime":"16:10 EDT","volume":3557,"amount":1047711.1487,"timestamp":1752869403876},"volumeRatio":1.826191,"impliedVol":0.5068,"impliedVolPercentile":0.8519},"requestUrl":"/m/hq/s/ONC","defaultTab":"news","newsList":[{"id":"2552626304","title":"百济神州(ONC)盘前涨近4% 机构料公司第二季收入按年升33%至12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552626304","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552626304?lang=zh_cn&edition=full","pubTime":"2025-07-18 19:26","pubTimestamp":1752837999,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州(ONC)盘前涨近4%，截至发稿，报301.260美元 。 消息面上，野村发表报告，料百济神州第二季收入按年升33%至12亿美元，与市场预期一致。该行预测百悦泽维持市场领导地位，次季销售按年升39%至8.84亿美元，其中美欧销售分别按年升35%及80%，至6.47亿及1.4亿美元。百泽安内地市场销售料按年升15%至1.82亿美元。此外，摩根大通分析师Jessica Fye维持百济神州买入评级，并将目标价从321美元上调至345美元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"290592","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","06160","LU2328871848.SGD","BK4526","BK4139","BK0239","LU0588546209.SGD","BK1588","688235","ONC","LU0307460666.USD","BK1161","LU1969619763.USD","BK1583"],"gpt_icon":0},{"id":"2552459051","title":"百济神州7月17日成交额为2.34亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552459051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552459051?lang=zh_cn&edition=full","pubTime":"2025-07-18 12:31","pubTimestamp":1752813112,"startTime":"0","endTime":"0","summary":"美东时间2025年7月17日，百济神州成交额为2.34亿美元，成交额较昨日增加72.38%，当日成交量为80.49万股。百济神州于2025年7月17日涨4.01%，报290.35美元，该股过去5个交易日涨14.59%，年初至今涨57.19%，过去60日涨26.67%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718123153a6b135fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718123153a6b135fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2552412721","title":"百济神州-U股价微跌0.56% 生物制药板块活跃度受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2552412721","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552412721?lang=zh_cn&edition=full","pubTime":"2025-07-17 01:56","pubTimestamp":1752688566,"startTime":"0","endTime":"0","summary":"百济神州-U7月16日收盘报239.94元，较前一交易日下跌0.56%。当日股价波动区间为237.79元至246.28元，成交金额达5.01亿元。该公司属于生物制品行业，专注于创新型分子靶向药物和肿瘤免疫药物的研发。作为一家全球性生物科技公司，百济神州在肿瘤治疗领域拥有多个在研产品管线。7月16日数据显示，百济神州-U主力资金净流出2927.45万元。该股当前总市值为3694.74亿元，流通市值276.06亿元。风险提示：股市有风险，投资需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702031197a8b94d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702031197a8b94d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","06160","ONC","688235"],"gpt_icon":0},{"id":"2551140802","title":"小细胞肺癌或将迎来首个BiTE新疗法，百济神州塔拉妥单抗申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2551140802","media":"新浪医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551140802?lang=zh_cn&edition=full","pubTime":"2025-07-16 19:15","pubTimestamp":1752664513,"startTime":"0","endTime":"0","summary":"2025年7月16日，国家药品监督管理局药品审评中心网站显示，百济神州的注射用塔拉妥单抗上市申报获受理。SCLC约占所有肺癌病例的15%,，其中大约70%的SCLC患者初始诊断时即为ES-SCLC。据悉，塔拉妥单抗由安进公司研发。未来，双方将继续拓展塔拉妥单抗的应用范围，加速更多适应症申报上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716192041a44e9ea7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716192041a44e9ea7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","688235","BK4526","06160","ONC"],"gpt_icon":0},{"id":"2551576142","title":"高管减持迪哲医药另一面：全球化战略会是下个百济神州吗？【医药视界】","url":"https://stock-news.laohu8.com/highlight/detail?id=2551576142","media":"投资者网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551576142?lang=zh_cn&edition=full","pubTime":"2025-07-16 18:01","pubTimestamp":1752660075,"startTime":"0","endTime":"0","summary":"减持释放什么信号迪哲医药进入一个高层减持密集期。其中，吴清漪减持金额超1900万元，股份来源于股权激励及二级市场增持。截至目前，公司仍无控股股东、实际控制人。获批上市后，该药被成功纳入医保。公司表示，两款药品纳入医保目录后，销量大幅增加。最为市场熟知的，是百济神州的泽布替尼。受此因素，该药成功在欧美获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716180622a6ad36ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716180622a6ad36ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688192","BK4526","688235","06160","BK4139"],"gpt_icon":0},{"id":"2551149731","title":"百济神州7月15日成交额为1.81亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551149731","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551149731?lang=zh_cn&edition=full","pubTime":"2025-07-16 12:39","pubTimestamp":1752640775,"startTime":"0","endTime":"0","summary":"美东时间2025年7月15日，百济神州成交额为1.81亿美元，成交额较昨日增加575.75%，当日成交量为67.44万股。百济神州于2025年7月15日涨6.96%，报269.7美元，该股过去5个交易日涨10.32%，年初至今涨46.01%，过去60日涨18.22%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716123942a44dcfb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716123942a44dcfb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2551119280","title":"科创成长层改革推进 券商系统升级及风险揭示书签署有序展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2551119280","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551119280?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:13","pubTimestamp":1752635582,"startTime":"0","endTime":"0","summary":"上交所方面正组织风险揭示书签署工作，并修订相关指南，新增《科创板科创成长层企业股票投资风险揭示书必备条款》，明确未盈利企业存在的各类投资风险。上交所下发通知要求券商完善适当性管理工作，包括完成风险揭示书签署及系统准备，给予投资者充分阅读时间，并通过多种渠道开展投资者教育。上交所将持续督促券商并开展监督检查。7月14日，上交所举办专题培训会，120家券商330余名相关负责人参会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","688561","688512","688373","688327","688197","688387","688280","ONC","688277","688538","BK0239","688343","000690.SH","01877","688443","688515","688256","688266","688176","688382","688469","688322","688220","688192","688316","688221","688702","688165","02402","688549","688302","06160"],"gpt_icon":0},{"id":"2551216032","title":"2025全球制药50强排名揭晓，中国药企表现亮眼！","url":"https://stock-news.laohu8.com/highlight/detail?id=2551216032","media":"医药地理","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551216032?lang=zh_cn&edition=full","pubTime":"2025-07-15 19:46","pubTimestamp":1752580012,"startTime":"0","endTime":"0","summary":"近日，美国《制药经理人》杂志公布了2025全球制药企业50强排名。这一榜单依据2024年度处方药业务全球销售、核心产品收入以及研发投入等指标进行排名。中国药企上榜情况概览此次上榜的6家中国药企中，云南白药排名第33位，与去年持平，位居中国药企榜首。华东医药首次上榜，排名第41位。2025全球制药50强榜单中国药企的亮眼表现，是中国制药行业发展的一个重要里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715205051a44c7785&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715205051a44c7785&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","01276","06160","01177","SBHMY","600276","01093","ONC"],"gpt_icon":0},{"id":"2551156152","title":"医保商保双目录调整 生物医药午后涨幅扩大 荣昌生物涨逾8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551156152","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551156152?lang=zh_cn&edition=full","pubTime":"2025-07-15 14:18","pubTimestamp":1752560315,"startTime":"0","endTime":"0","summary":"截至发稿，荣昌生物涨8.37%，石药集团涨7.26%，诺诚健华涨6.95%，百济神州涨6.43%，中国生物制药涨4.61%，信达生物涨3.66%。消息面上，2025年国家基本医疗保险，生育保险和工伤保险药品目录及商业健康保险创新药品目录调整7月11日正式启动。世纪证券指出，创新药商保目录意味着国内医药多元支付体系重构，商业健康险将在创新药支付方面扮演更为重要的角色，高价创新药可及性有望进一步提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071514191497a6a43d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071514191497a6a43d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1152091754.HKD","LU1226287529.USD","LU0315179316.USD","LU1969619763.USD","688235","IE00BZ08YR35.GBP","LU1807302812.USD","LU1993786604.SGD","IE0008368742.USD","06160","LU0326950275.SGD","LU1226287875.USD","LU1960683339.HKD","IE00BZ08YT58.USD","688331","IE00B031HY20.USD","01801","LU0140636845.USD","BK1161","LU1226288170.HKD","01093","BK1521","01177","688428","BK1515","09995","LU0501845795.SGD","BK1191","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","LU1226287792.SGD","LU1008478684.HKD","LU1226288253.USD","LU0072913022.USD","SBHMY","IE0008369823.USD","LU0880133367.SGD","09969","LU1951186391.HKD","ONC","BK1583","LU0067412154.USD","LU1152091168.USD","IE00B543WZ88.USD","BK1574","LU2328871848.SGD","SG9999004220.SGD"],"gpt_icon":0},{"id":"2551909815","title":"7月14日百济神州-UAH溢价达62.22%，位居AH股溢价率第70位","url":"https://stock-news.laohu8.com/highlight/detail?id=2551909815","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551909815?lang=zh_cn&edition=full","pubTime":"2025-07-14 16:43","pubTimestamp":1752482632,"startTime":"0","endTime":"0","summary":"7月14日，上证指数涨0.27%，收报3519.65点，恒生指数涨0.26%，收报24203.32点。当日收盘，百济神州-UA股报225.94元，跌幅1.72%，H股报152.5港元，下跌1.04%。资料显示，百济神州有限公司是一家商业化阶段的生物技术公司,专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714164921a44970fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714164921a44970fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526","06160"],"gpt_icon":0},{"id":"2551130912","title":"2025年医保政策与产业动态：产业布局升级与行业监管强化","url":"https://stock-news.laohu8.com/highlight/detail?id=2551130912","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551130912?lang=zh_cn&edition=full","pubTime":"2025-07-13 08:05","pubTimestamp":1752365100,"startTime":"0","endTime":"0","summary":"中国报告大厅网讯，随着国家医疗保障体系的不断完善，2025年医保相关政策及医药产业发展呈现显著变化。国家医保局、药监局等机构通过政策引导与严格监管，进一步优化药品供给结构，并强化了对违法违规行为的打击力度。数据显示，2025年目录调整将直接影响超万种药品的市场准入资格。总结2025年医保政策与产业布局呈现多维度深化态势：目录动态调整优化资源配置、监管强化保障行业规范、资本助力推动技术创新。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071308112797a3ed86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071308112797a3ed86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK0239","ONC","02315","688235"],"gpt_icon":0},{"id":"2550986727","title":"百奥赛图与百济神州深化合作 达成抗体分子全球许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2550986727","media":"DoNews","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550986727?lang=zh_cn&edition=full","pubTime":"2025-07-11 14:57","pubTimestamp":1752217023,"startTime":"0","endTime":"0","summary":"百奥赛图近日宣布，与百济神州就抗体分子达成全球许可协议。此次合作是在百济神州已获百奥赛图RenMice®全人抗体平台授权的基础上，进一步拓展至具体抗体分子领域的授权许可，体现了双方在抗体研发方向上的持续协同与深入布局。此次协议的签署不仅强化了双方在创新生物药领域的合作关系，也显示出百奥赛图技术平台在全球新药开发中的重要价值。通过资源共享与优势互补，双方有望加速推进抗体药物的全球化开发进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071114591297a1f1a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071114591297a1f1a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","688235","ONC"],"gpt_icon":0},{"id":"2550677795","title":"这款国产 PD-1 在海外又有新消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2550677795","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550677795?lang=zh_cn&edition=full","pubTime":"2025-07-11 08:18","pubTimestamp":1752193081,"startTime":"0","endTime":"0","summary":"替雷利珠单抗联合化疗组中位 PFS 为 9.2 个月，而安慰剂联合化疗组为 7.4 个月。额外 12 个月随访更新分析显示，有效性结果与期中分析结果一致。替雷利珠单抗联合化疗总体耐受性良好，未发现新的安全性信号。替雷利珠单抗是百济神州自主研发的 PD-1 抑制剂，2019 年 12 月在国内获批，2023 年 9 月，替雷利珠单抗获得欧盟批准，用于治疗特定类型的食管鳞状细胞癌，成为 PD-1 领域首款“出海”产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711083536a6a27bde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711083536a6a27bde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","BK0239","ONC"],"gpt_icon":0},{"id":"2550641478","title":"百济神州：欧盟委员会批准百泽安联合化疗用于鼻咽癌患者一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2550641478","media":"南方财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550641478?lang=zh_cn&edition=full","pubTime":"2025-07-10 18:39","pubTimestamp":1752143991,"startTime":"0","endTime":"0","summary":"7月10日，百济神州宣布，欧盟委员会（EC）已批准百泽安?（替雷利珠单抗）联合吉西他滨和顺铂用于不适合根治性手术或放疗的转移或复发性鼻咽癌（NPC）成年患者的一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507103453490572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0307460666.USD","06160","BK1161","BK4139","LU1969619763.USD","BK1588","LU2328871848.SGD","BK1500","ONC","LU0588546209.SGD","BK1583","BK4526"],"gpt_icon":0},{"id":"2550694920","title":"百济神州7月9日成交额为9172.04万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550694920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550694920?lang=zh_cn&edition=full","pubTime":"2025-07-10 12:37","pubTimestamp":1752122269,"startTime":"0","endTime":"0","summary":"美东时间2025年7月9日，百济神州成交额为9172.04万美元，成交额较昨日增加41.27%，当日成交量为36.11万股。百济神州于2025年7月9日涨4.59%，报255.69美元，该股过去5个交易日涨4.3%，年初至今涨38.43%，过去60日涨22.74%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710123750a6a0c521&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710123750a6a0c521&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2550661203","title":"百奥赛图与百济神州达成抗体分子许可协议，加速创新药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2550661203","media":"美国商业资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550661203?lang=zh_cn&edition=full","pubTime":"2025-07-10 00:00","pubTimestamp":1752076800,"startTime":"0","endTime":"0","summary":"-- 百奥赛图，一家创新技术驱动新药研发的国际性生物技术公司，今日宣布与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。根据协议条款，百济神州将向百奥赛图支付首付款。关于百济神州百济神州是一家注册地位于瑞士的全球肿瘤治疗创新公司，专注于为全世界的癌症患者研发创新抗肿瘤药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710080113a6a041c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710080113a6a041c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","BK1574","LU0307460666.USD","06160","BK1500","BK1161","06978","688235","LU1969619763.USD","LU2328871848.SGD","ONC","BK1588","02315","BK1583"],"gpt_icon":0},{"id":"2550659831","title":"百济神州美股涨逾3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550659831","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550659831?lang=zh_cn&edition=full","pubTime":"2025-07-09 22:06","pubTimestamp":1752069960,"startTime":"0","endTime":"0","summary":"每经AI快讯，7月9日，百济神州美股涨逾3%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-07-09/doc-infewutf4583769.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-07-09/doc-infewutf4583769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","688235","BK4526","BK0239","BK1500","LU0588546209.SGD","ONC","LU0307460666.USD","LU1969619763.USD","06160","BK4139","BK1583","LU2328871848.SGD","BK1588"],"gpt_icon":0},{"id":"2550504187","title":"百济神州7月8日成交额为6492.56万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550504187","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550504187?lang=zh_cn&edition=full","pubTime":"2025-07-09 12:35","pubTimestamp":1752035720,"startTime":"0","endTime":"0","summary":"美东时间2025年7月8日，百济神州成交额为6492.56万美元，成交额较昨日减少16.17%，当日成交量为26.57万股。百济神州于2025年7月8日涨1.44%，报244.47美元，该股过去5个交易日涨0.99%，年初至今涨32.35%，过去60日涨18.49%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709123521a69e8b81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709123521a69e8b81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2550284503","title":"刚刚，原百济神州大中华区CFO去向曝光！","url":"https://stock-news.laohu8.com/highlight/detail?id=2550284503","media":"CFO职业圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550284503?lang=zh_cn&edition=full","pubTime":"2025-07-09 10:14","pubTimestamp":1752027296,"startTime":"0","endTime":"0","summary":"时隔4个月，他的新职位终于公布。详见《重磅！百济神州大中华区CFO离职》。加入亚盛医药之前，黄智先生担任百济神州大中华区和亚太区首席财务官、全球技术运营和全球商业财务负责人。在百济任职期间，他通过完整的全面预算管理及合理的全球布局资源优化，持续改善公司财务状况。据Veet Misra的领英资料，其工作经历详细如下：温馨提示关注并星标“CFO职业圈”，不错过每一篇新推送！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102329a43f2ee2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102329a43f2ee2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688235","BK0239","ONC"],"gpt_icon":0},{"id":"2549510933","title":"百济神州 DLL3/CD3 双抗拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2549510933","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549510933?lang=zh_cn&edition=full","pubTime":"2025-07-08 17:11","pubTimestamp":1751965869,"startTime":"0","endTime":"0","summary":"7 月 8 日，CDE 官网显示，百济神州申报的注射用塔拉妥单抗拟纳入优先审评，用于既往接受过至少 2 线治疗失败的广泛期小细胞肺癌成人患者的治疗。2025 年 5 月，百济神州宣布，与安进公司在中国联合开展的注射用塔拉妥单抗2 期临床研究 DeLLphi-307 已取得积极结果。基于 DeLLphi-301、DeLLphi-304 和 DeLLphi-307 研究所获得的积极结果，塔拉妥单抗有望为中国 SCLC 患者的二线、三线及后线治疗提供新的用药选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708171749a43db9a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708171749a43db9a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK1500","BK1583","LU0307460666.USD","ONC","LU2328871848.SGD","BK1588","688235","BK1161","06160","LU0588546209.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.1459},{"period":"1month","weight":0.1427},{"period":"3month","weight":0.257},{"period":"6month","weight":0.3821},{"period":"1year","weight":0.8898},{"period":"ytd","weight":0.5719}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":0.0511},{"period":"3month","weight":0.1931},{"period":"6month","weight":0.051},{"period":"1year","weight":0.1277},{"period":"ytd","weight":0.0716}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"　　百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.079635},{"month":2,"riseRate":0.666667,"avgChangeRate":0.038229},{"month":3,"riseRate":0.4,"avgChangeRate":-0.025903},{"month":4,"riseRate":0.4,"avgChangeRate":0.021288},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019094},{"month":6,"riseRate":0.5,"avgChangeRate":0.012468},{"month":7,"riseRate":0.8,"avgChangeRate":0.142755},{"month":8,"riseRate":0.555556,"avgChangeRate":0.036185},{"month":9,"riseRate":0.555556,"avgChangeRate":0.064683},{"month":10,"riseRate":0.555556,"avgChangeRate":0.004837},{"month":11,"riseRate":0.555556,"avgChangeRate":0.060012},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.03651}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,ONC,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}